GET DAILY SIGNALSTG Therapeutics (TGTX) Eyes +25% Upside to $79 on BRIUMVI Strength
Key Takeaways
- The central target of $79 is the arithmetic mean of the five verified analyst price targets that sit above the current share price, not an official published consensus.
- The overall mean of all seven verified analyst targets is about $65, with a wide range from $21 (Bank of America, Sell) to $86 (B. Riley, Buy).
- The latest market price is roughly $63.36, meaning the stock would need to rise about 25% to reach $79.
- The strongest support is BRIUMVI's commercial momentum in relapsing multiple sclerosis, reinforced by a raised full-year 2026 revenue target near $950 million.
- The biggest risks are competition in the CD20 multiple sclerosis market, the potential for a subcutaneous formulation to cannibalize or reshape demand, and a notably bearish outlier view from Bank of America.
- You can follow Major News, Today's Price Move, the Forecast, and Earnings on dedicated pages for deeper, up-to-date coverage.
- For automated, AI-driven market screening and trade ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company whose lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. Because TGTX is a stock with multiple current, attributed targets, analyst estimates are the primary input for the central target here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Seven recent, verifiable price targets were reviewed: TD Cowen at $75 (Nov. 9, 2026), H.C. Wainwright at $78 (Sept. 21, 2026), B. Riley Securities at $86 (Sept. 2, 2026), Jefferies at $83 (July 14, 2026), J.P. Morgan at $72 (Aug. 7, 2026), Goldman Sachs at $41 (June 4, 2026), and Bank of America at $21 (Aug. 5, 2026). The range is unusually wide, from $21 to $86.
The overall mean of those seven targets is about $65, only marginally above the latest price. Because that mean fails to clear the 10% minimum-distance threshold, the central target is instead the average of the five targets above the current price, which calculates to $78.80 and rounds to $79. The full context—a roughly $65 overall mean and a $21–$86 range—shows genuine disagreement rather than a tidy "analyst consensus."
The divide is stark. Bullish analysts emphasize accelerating BRIUMVI revenue and a future subcutaneous formulation, while Bank of America maintains a Sell and a $21 target on competitive and valuation concerns, and Goldman Sachs holds a Neutral rating with a $41 target.
Current Market Position and Path Toward the Target
With the stock near $63.36, reaching $79 implies an upside of roughly 25%, a substantial move. The shares have climbed sharply from a 52-week low near $27, now trading above prior 52-week highs—a sign of strong momentum but also a setup where expectations are already elevated.
Fundamentally, the path depends on sustained BRIUMVI demand and earnings per share (EPS) growth. The company's most recent quarterly report showed revenue of about $259.9 million, exceeding estimates, alongside EPS of $0.35 that narrowly missed. Full-year 2026 revenue guidance has been raised toward approximately $950 million. A 25% move is not trivially small, but it is within the range implied by the bullish half of the analyst group. From what I see, this setup warrants close monitoring of upcoming quarters.
What Could Support a Move Toward the Target
- BRIUMVI commercial execution: Rising U.S. net product revenue and repeated guidance increases are the core bull case.
- Subcutaneous opportunity: A subcutaneous version could broaden the addressable market and extend the franchise, a recurring theme in bullish research.
- Upward target revisions: B. Riley raised its target to $86, and J.P. Morgan lifted its objective to $72, reflecting improving visibility.
- Pipeline optionality: Earlier-stage assets such as TG-1701 and TG-1801 provide additional, longer-dated upside.
What Could Prevent the Target From Being Reached
- Competitive pressure: The CD20 multiple sclerosis market is crowded, and oral competitors could erode BRIUMVI's positioning.
- Valuation and execution risk: Bank of America's $21 Sell target reflects skepticism that growth can justify the current multiple.
- EPS estimates: Consensus EPS has been revised lower in some periods, even as revenue forecasts rose, signaling margin uncertainty.
- Concentration risk: The investment case remains heavily tied to a single product, BRIUMVI.
Technical Levels and Market Structure
The stock has broken above its prior 52-week high, which can now act as a reference point, while the broader multi-month range from roughly $27 to the low-$60s shows how far the shares have traveled. A decisive hold above former highs would support the bullish technical case, whereas a retreat back below them would suggest the breakout is fading. The $79 target sits well above recent consolidation, so reaching it would require a sustained leg higher rather than a routine move.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Key items to watch include quarterly BRIUMVI sales and any updates to full-year guidance, EPS trends, developments on the subcutaneous program, competitive launches or data readouts, and further analyst revisions. Regulatory and reimbursement decisions tied to BRIUMVI's expansion would also matter. I’m watching this closely as new data emerges.
Using AI Tools in My Analysis
In my research, I often turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifting market conditions for stocks like this one. The platform applies artificial intelligence to monitor thousands of securities and generate Buy, Sell, or Hold signals based on technical patterns and market behavior. It serves as a helpful layer alongside traditional research without replacing independent judgment.
Final Assessment
Can TGTX reach $79? The target is achievable only if the bullish half of the analyst community is right. That group's average objective of $79 requires roughly a 25% advance, backed by BRIUMVI's commercial momentum and a potential subcutaneous catalyst. Against that, a $21 Sell target from Bank of America and a $41 Hold from Goldman Sachs underscore how divergent the Street's views are. With an overall mean near $65 and an extremely wide $21–$86 range, this is not a case of broad agreement. Investors should weigh the product's execution record against competitive and valuation risks, and watch upcoming earnings and guidance updates before drawing any conclusion.
Promo Section
In my own workflow, Tickeron’s AI Daily Buy/Sell Signals has become a go-to resource for tracking momentum shifts across the market. The tool scans thousands of stocks and ETFs daily, delivering signals derived from technical patterns and AI analysis. It helps me identify opportunities and monitor positions more efficiently while I continue to apply my own judgment to each idea.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TGTX in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TGTX as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on October 27, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
TGTX moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 253 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 177 of 226 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 35 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 62 cases where TGTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
TGTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.159) is normal, around the industry mean (3.498). P/E Ratio (19.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement